drugset / Trial / NCT05789043
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.
Timeline
- Start
- 2023-03-21
- Primary completion
- 2026-08-15
- Completion
- 2027-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Rivoceranib | Small molecule | 250 mg | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |
| Comparator | Camrelizumab | Monoclonal antibody | 200 mg | — |